Kenya - anglès - Pharmacy and Poisons Board

yuria-pharm ltd. 10, amosova str. kyiv, ukraine - l-arginini hydrochloridum - solution for infusion - 1 ml contains 42 mg of arginine hydrochloride… - arginine hydrochloride

Estats Units - anglès - NLM (National Library of Medicine)

physician therapeutics llc - tramadol hydrochloride (unii: 9n7r477wck) (tramadol - unii:39j1lgj30j) - tramadol hydrochloride 50 mg - indications and usage tramadol hydrochloride tablets are indicated for the management of moderate to moderately severe pain in adults. contraindications tramadol hydrochloride tablets should not be administered to patients who have previously demonstrated hypersensitivity to tramadol, any other component of this product or opioids. tramadol hydrochloride is contraindicated in any situation where opioids are contraindicated, including acute intoxication with any of the following: alcohol, hypnotics, narcotics, centrally acting analgesics, opioids or psychotropic drugs. tramadol may worsen central nervous system and respiratory depression in these patients. pediatric use the safety and efficacy of tramadol hydrochloride in patients under 16 years of age have not been established. the use of tramadol hydrochloride in the pediatric population is not recommended. geriatric use in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the g

Estats Units - anglès - NLM (National Library of Medicine)

physician therapeutics llc - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - hydrocodone bitartrate 10 mg - indications and usage hydrocodone bitartrate and acetaminophen tablets, usp are indicated for the relief of moderate to moderately severe pain. contraindications hydrocodone bitartrate and acetaminophen tablets, usp should not be administered to patients who have previously exhibited hypersensitivity to hydrocodone or acetaminophen, or any other component of this product. patients known to be hypersensitive to other opioids may exhibit cross-sensitivity to hydrocodone. pediatric use safety and effectiveness in pediatric patients have not been established. geriatric use clinical studies of hydrocodone bitartrate and acetaminophen did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, re

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; hyprolose; magnesium stearate; isomalt; colloidal anhydrous silica; hypromellose; macrogol 8000 - treatment of hypertension and the treatment of heart failure. in such patients it is recommended that perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 5 mg - tablet, film coated - excipient ingredients: iron oxide yellow; isomalt; magnesium stearate; hypromellose; brilliant blue fcf aluminium lake; titanium dioxide; hyprolose; colloidal anhydrous silica; macrogol 8000 - treatment of hypertension and the treatment of heart failure. in such patients it is recommended that perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 10 mg - tablet, film coated - excipient ingredients: iron oxide yellow; colloidal anhydrous silica; hypromellose; isomalt; titanium dioxide; macrogol 8000; magnesium stearate; brilliant blue fcf aluminium lake; hyprolose - treatment of hypertension and the treatment of heart failure. in such patients it is recommended that perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - arginine hydrochloride, quantity: 600 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - indications as at 01 jan 1991 : arginine stimulates the release of growth hormone by the pituitary gland and may be used instead of , or in addition to, other tests such as insulin-induced hypoglycaemia, for the evaluation of growth disorders; false positive and false negative results are relatively common and evaluation therefore should not be made on the basis of a single arginine test. arginine is used as an acidifying agent in severe metabolic alkalosis. arginine is used in some conditions accompanied by hyperammonaemia stemming from inborn errors of the urea cycle, particularly where there is a severe deficiency of ornithine carbamoyl transferase or carbamoyl phosphate synthetase where respiratory alkalosis is present.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - perindopril arginine -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - perindopril arginine -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - perindopril arginine -